Back

Bridging the gap: real-world eligibility for lipoprotein(a)-targeted therapies in chronic and acute coronary syndrome

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering (1) Drug therapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Eva Steinacher

Medical University of Vienna, Vienna (Austria)

6 More presentations in this session

Presentation thumbnail
LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy
Doctor K. Mahajan (Mandi, IN)
Abstract Slides Video
Presentation thumbnail
Association of LDL-C/ApoB ratio with pathogenic variants in familial hypercholesterolemia
Doctor F. Wollmann (Wien, AT)
Abstract Slides Video
Presentation thumbnail
Real-world efficacy and tolerability of lipid-lowering therapy in children with monogenic familial hypercholesterolemia in primary care
Mr R. Schmieder (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Association of apolipoprotein B and lipoprotein(a) with severe atherosclerotic cardiovascular disease in patients with acute coronary syndrome: the modifying effect of prior lipid-lowering therapy.
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides Video
Presentation thumbnail
Elective coronary revascularisation represents an unutilised opportunity to optimise lipid management: results from a multicentre observational cohort
Miss M. van den Bogaart (Amsterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid lowering (1)

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Serial lipoprotein(a) measurements reclassify cardiovascular risk and identify additional candidates for lipoprotein(a)-lowering therapy
29 August 2026
thumbnail
Congress Presentation
Comparative effectiveness of lipid-lowering regimens for achieving ESC LDL-cholesterol targets in acute coronary syndrome: a real-world cohort analysis
31 August 2026
thumbnail
Congress Presentation
Does lipoprotein(a) associate with coronary high-risk plaque in patients without hypercholesterolemia? Insights from optical coherence tomography imaging
29 August 2026
thumbnail
Congress Presentation
Elevated lipoprotein(a) is associated with increased inflammatory and myocardial injury markers in acute coronary syndrome patients undergoing percutaneous coronary intervention
31 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources